This usually balances out within a week or two as your body adjusts
For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs
For oral semaglutide, follow the strict fasting requirements (take 30 minutes before first food or other medications with no more than 4 ounces of water)
Visual inspection before each injection is a critical safety practice for all GLP-1 medication users
Most-engaged members lost 25.2% more weight at week 40 and persisted 2.2x longer on medication program than least-engaged members using the Noom app, demonstrating the benefits of combining GLP-1 medication with Nooms GLP-1 Companion behavior-change program PRINCETON, N.J., February 4, 2026 Noom, the leading behavior change company, today shared new real-world findings from tens of thousands of members, showing a clear relationship: members who engage more with Nooms leading GLP-1 Companion app tend to lose more weight and stay on a medication program longer
conducted target trial emulations comparing dual GLP-1/GIP agonists to GLP-1 monotherapy in patients with type 2 diabetes, finding that dual agonists were linked to numerically lower risks of MALOs, although confidence intervals overlapped, suggesting that extended observation period and larger patient cohorts may be needed to definitively establish comparative effectiveness [61]
